CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...

U.S. President Donald Trump has repeatedly mentioned pharmaceuticals as another industry that could be targeted by tariffs, ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Suzetrigine (Journavx) is the first non-opioid pain medication to be approved in the US in 20 years. It could help over 80 million Americans living with severe acute pain, while reducing the effects ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

Vertex Pharmaceuticals’ suzetrigine gets US FDA approval for treatment of adults with moderate-to-severe acute pain: Boston Saturday, February 1, 2025, 14:00 Hrs [IST] Vertex Ph ...

This new nonaddictive alternative is the first of its kind that interrupts the pain signal before it reaches the brain.

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...